Europe Cancer Screening Market (2018-2023)
The report is sent in 5-10 business days after order is placed.
Europe cancer screening market
Europe after North America is the second largest market leading the cancer screening market. The market is forecasted to grow at a compound annual growth rate of (CAGR) of 8.1% resulting in an annual revenue of USD 22.43 Bn during the forecast period (2018-2023). Increase in the aging population along with the rise in the number of cancer incidences is a key driving factor for the market. Western Europe is moving fast towards the adoption of performance-based remuneration systems.
By end users, the market is segmented into hospitals, laboratories and independent physicians and clinics. The Laboratory segment will witness a progressive growth during the forecast period 2018-2023 while the hospital segment will account for the maximum revenue of USD 11.18 billion during the forecast period.
By screening type, the market is segmented into laboratory, genetic, imaging, biopsy and endoscopy tests. Genetic, biopsy and endoscopy will be the leading segments during the forecast period 2018-2023.
By application type, the market can be segmented into lung, breast, melanoma, kidney and colorectal cancer types. Colorectal, kidney, melanoma and breast cancer will occupy a larger share of the market during the forecast period 2018-2023.
By countries, the market is divided into the United Kingdom (U.K.), France and Germany.
Key growth factors
Rise in the aging population, changing environmental conditions along with the adoption of a sedentary lifestyle is contributing to more cancer-related cases.
Threats and key players
Stringent regulations along with regulatory inter and intra state barriers pose many challenges for the region. Lack of associated funding and transparency in medical procedures turn out to be as threats to the market.
Key players in the European cancer screening market are F. Hoffman-La- Roche Ltd, Bayer AG, and Johnson & Johnson, Pfizer, Merck & co.
What is covered in the report?
1. Overview of the European cancer screening market.
2. Market drivers and challenges in the European cancer screening market.
3. Market trends in the European cancer screening market.
4. Historical, current and forecasted market size data for Europe market segmentation based on type of end users (hospitals, laboratories, independent physicians and clinics) – by type of screening (laboratory, genetic, imaging, biopsy and endoscopy) –by application (lung, breast, melanoma, kidney and colorectal).
5. Historical, current and forecasted market size data for Europe market segmentation based on end-users (hospitals, laboratories, independent physicians and clinics) – by type of screening type(laboratory, genetic, imaging, biopsy and endoscopy) –by application (lung, breast, melanoma, kidney and colorectal).
6. Historical, current and forecasted market size data of the cancer screening market by countries UK, Germany and Others (Other parts of Europe) – by revenue.
7. Historical, current and forecasted market size data for country-wise segments – by revenue.
8. Analysis of the competitive landscape and profiles of major competitors operating in the European market.
Why buy?
Customizations available
With the given market data, Netscribes offers customizations according to specific needs.
Europe cancer screening market
Europe after North America is the second largest market leading the cancer screening market. The market is forecasted to grow at a compound annual growth rate of (CAGR) of 8.1% resulting in an annual revenue of USD 22.43 Bn during the forecast period (2018-2023). Increase in the aging population along with the rise in the number of cancer incidences is a key driving factor for the market. Western Europe is moving fast towards the adoption of performance-based remuneration systems.
By end users, the market is segmented into hospitals, laboratories and independent physicians and clinics. The Laboratory segment will witness a progressive growth during the forecast period 2018-2023 while the hospital segment will account for the maximum revenue of USD 11.18 billion during the forecast period.
By screening type, the market is segmented into laboratory, genetic, imaging, biopsy and endoscopy tests. Genetic, biopsy and endoscopy will be the leading segments during the forecast period 2018-2023.
By application type, the market can be segmented into lung, breast, melanoma, kidney and colorectal cancer types. Colorectal, kidney, melanoma and breast cancer will occupy a larger share of the market during the forecast period 2018-2023.
By countries, the market is divided into the United Kingdom (U.K.), France and Germany.
Key growth factors
Rise in the aging population, changing environmental conditions along with the adoption of a sedentary lifestyle is contributing to more cancer-related cases.
Threats and key players
Stringent regulations along with regulatory inter and intra state barriers pose many challenges for the region. Lack of associated funding and transparency in medical procedures turn out to be as threats to the market.
Key players in the European cancer screening market are F. Hoffman-La- Roche Ltd, Bayer AG, and Johnson & Johnson, Pfizer, Merck & co.
What is covered in the report?
1. Overview of the European cancer screening market.
2. Market drivers and challenges in the European cancer screening market.
3. Market trends in the European cancer screening market.
4. Historical, current and forecasted market size data for Europe market segmentation based on type of end users (hospitals, laboratories, independent physicians and clinics) – by type of screening (laboratory, genetic, imaging, biopsy and endoscopy) –by application (lung, breast, melanoma, kidney and colorectal).
5. Historical, current and forecasted market size data for Europe market segmentation based on end-users (hospitals, laboratories, independent physicians and clinics) – by type of screening type(laboratory, genetic, imaging, biopsy and endoscopy) –by application (lung, breast, melanoma, kidney and colorectal).
6. Historical, current and forecasted market size data of the cancer screening market by countries UK, Germany and Others (Other parts of Europe) – by revenue.
7. Historical, current and forecasted market size data for country-wise segments – by revenue.
8. Analysis of the competitive landscape and profiles of major competitors operating in the European market.
Why buy?
- Understand the demand for the cancer screening market to determine the viability of the market.
- Understand the country-specific market size and observations for each segment.
- Develop strategies based on the drivers, trends and highlights for each of the segments.
- Evaluate the value chain to determine the workflow and to get an idea of the current position where you are placed.
- Recognize the key competitors of this market and respond accordingly.
- Identify the initiatives and growth strategies taken by the major companies and decide the direction of further growth.
- Define the competitive positioning by comparing the products and services compared with the key players in the market
Customizations available
With the given market data, Netscribes offers customizations according to specific needs.
CHAPTER 1: EXECUTIVE SUMMARY
1.1 Market scope and segmentation
1.2 Key questions answered in this study
1.3 Executive summary
CHAPTER 2: EUROPE CANCER SCREENING MARKET – MARKET OVERVIEW
2.1. Europe market overview – market trends, market attractiveness analysis, country-wise market revenue (USD)
2.2. Europe – market drivers and challenges
2.3. Value chain analysis – cancer screening market
2.4. Porter’s five forces analysis
2.5. Market segmentation based on type of end users (hospitals, laboratory, independent physicians and clinics)
2.5. a. Hospitals Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.5. b. Laboratory Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.5. c. Independent physicians and clinics revenue Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.5. d. Growth drivers and key challenges
2.6. Market segmentation based on type of screening (Laboratory, genetic, imaging, biopsy and endoscopy) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
2.6. a. Laboratory Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6. b. Genetic Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6. c. Imaging Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6. d. Biopsy Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6. e. Endoscopy Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6. f. Growth drivers and key challenges
2.7. Market segmentation based on type of application (lung, breast, melanoma, kidney and colorectal) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
2.7. a. Lung Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.7. b. Breast Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.7. c. Melanoma Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.7. d. Kidney Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.7. e. Colorectal Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.7. f. Growth drivers and key challenges
2.8. Major country penetration
CHAPTER 3. THE UK CANCER SCREENING MARKET
3.1. The UK market overview – market trends, market attractiveness analysis, country-wise market revenue (USD)
3.2. Market segmentation based on type of end users (hospitals, laboratory, independent physicians and clinics)
3.2. a. Hospitals Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2. b. Laboratory Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2. c. Independent physicians and clinics revenue Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2. d. Growth drivers and key challenges
3.3. Market segmentation based on type of screening (laboratory, genetic, imaging, biopsy and endoscopy) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
3.3. a. Laboratory Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3. b. Genetic Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3. c. Imaging Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3. d. Biopsy Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3. e. Endoscopy Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3. f. Growth drivers and key challenges
3.4. Market segmentation based on type of application (lung, breast, melanoma, kidney and colorectal) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
3.4. a. Lung Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.4. b. Breast Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.4. c. Melanoma Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.4. d. Kidney Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.4. e. Colorectal Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.4. f. Growth drivers and key challenges
CHAPTER 4. GERMANY CANCER SCREENING MARKET
4.1. Germany market overview – market trends, market attractiveness analysis, country-wise market revenue (USD)
4.2. Market segmentation based on type of end users (hospitals, laboratory, independent physicians and clinics)
4.2. a. Hospitals Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.2. b. Laboratory Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.2. c. Independent physicians and clinics revenue Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.2. d. Growth drivers and key challenges
4.3. Market segmentation based on type of screening (laboratory, genetic, imaging, biopsy and endoscopy) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
4.3. a. Laboratory Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.3. b. Genetic Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.3. c. Imaging Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.3. d. Biopsy Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.3. e. Endoscopy Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.3. f. Growth drivers and key challenges
4.4. Market segmentation based on type of application (lung, breast, melanoma, kidney and colorectal) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
4.4. a. Lung Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.4. b. Breast Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.4. c. Melanoma Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.4. d. Kidney Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.4. e. Colorectal Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.4. f. Growth drivers and key challenges
CHAPTER 5. OTHERS (THE REST OF EUROPE) CANCER SCREENING MARKET
5.1. Others (the rest of Europe) market overview – market trends, market attractiveness analysis, country-wise market revenue (USD)
5.2. Market segmentation based on type of end users (hospitals, laboratory, independent physicians and clinics)
5.2. a. Hospitals Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.2. b. Laboratory Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.2. c. Independent physicians and clinics revenue Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.2. d. Growth drivers and key challenges
5.3. Market segmentation based on the type of screening type (laboratory, genetic, imaging, biopsy and endoscopy) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
5.3. a. Laboratory Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.3. b. Genetic Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.3. c. Imaging Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.3. d. Biopsy Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.3. e. Endoscopy Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.3. f. Growth drivers and key challenges
5.4. Market segmentation based on type of application (lung, breast, melanoma, kidney and colorectal) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
5.4. a. Lung Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.4. b. Breast Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.4. c. Melanoma Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.4. d. Kidney Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.4. e. Colorectal Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.4. f. Growth drivers and key challenges
CHAPTER 6: COMPETITIVE LANDSCAPE
6.1. F. Hoffman La Roche Ltd
6.1. a. Company snapshot
6.1. b. Product offerings
6.1. c. Growth strategies
6.1. d. Initiatives
6.1. e. Geographical presence
6.1. f. Key numbers
6.2. Bayer AG
6.2. a. Company snapshot
6.2. b. Product offerings
6.2. c. Growth strategies
6.2. d. Initiatives
6.2. e. Geographical presence
6.2. f. Key numbers
6.3. Johnson & Johnson
6.3. a. Company snapshot
6.3. b. Product offerings
6.3. c. Growth strategies
6.3. d. Initiatives
6.3. e. Geographical presence
6.3. f. Key numbers
6.4. Pfizer
6.4. a. Company snapshot
6.4. b. Product offerings
6.4. c. Growth strategies
6.4. d. Initiatives
6.4. e. Geographical presence
6.4. f. Key numbers
6.5. Merck & Co.
6.5. a. Company snapshot
6.5. b. Product offerings
6.5. c. Growth strategies
6.5. d. Initiatives
6.5. e. Geographical presence
6.5. f. Key numbers
CHAPTER 7: CONCLUSION
CHAPTER 8: APPENDIX
8.1. List of tables
8.2. Assumptions
8.3. Research and methodology
8.4. About Netscribes Inc.
Note: The Table of Contents (Toc) provided above contains the targeted coverage. The coverage is subject to change as we progress with the research.
Disclaimer: The report will be delivered within 5-7 business days post payment confirmation
1.1 Market scope and segmentation
1.2 Key questions answered in this study
1.3 Executive summary
CHAPTER 2: EUROPE CANCER SCREENING MARKET – MARKET OVERVIEW
2.1. Europe market overview – market trends, market attractiveness analysis, country-wise market revenue (USD)
2.2. Europe – market drivers and challenges
2.3. Value chain analysis – cancer screening market
2.4. Porter’s five forces analysis
2.5. Market segmentation based on type of end users (hospitals, laboratory, independent physicians and clinics)
2.5. a. Hospitals Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.5. b. Laboratory Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.5. c. Independent physicians and clinics revenue Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.5. d. Growth drivers and key challenges
2.6. Market segmentation based on type of screening (Laboratory, genetic, imaging, biopsy and endoscopy) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
2.6. a. Laboratory Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6. b. Genetic Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6. c. Imaging Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6. d. Biopsy Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6. e. Endoscopy Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6. f. Growth drivers and key challenges
2.7. Market segmentation based on type of application (lung, breast, melanoma, kidney and colorectal) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
2.7. a. Lung Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.7. b. Breast Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.7. c. Melanoma Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.7. d. Kidney Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.7. e. Colorectal Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.7. f. Growth drivers and key challenges
2.8. Major country penetration
CHAPTER 3. THE UK CANCER SCREENING MARKET
3.1. The UK market overview – market trends, market attractiveness analysis, country-wise market revenue (USD)
3.2. Market segmentation based on type of end users (hospitals, laboratory, independent physicians and clinics)
3.2. a. Hospitals Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2. b. Laboratory Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2. c. Independent physicians and clinics revenue Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2. d. Growth drivers and key challenges
3.3. Market segmentation based on type of screening (laboratory, genetic, imaging, biopsy and endoscopy) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
3.3. a. Laboratory Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3. b. Genetic Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3. c. Imaging Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3. d. Biopsy Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3. e. Endoscopy Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3. f. Growth drivers and key challenges
3.4. Market segmentation based on type of application (lung, breast, melanoma, kidney and colorectal) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
3.4. a. Lung Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.4. b. Breast Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.4. c. Melanoma Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.4. d. Kidney Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.4. e. Colorectal Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.4. f. Growth drivers and key challenges
CHAPTER 4. GERMANY CANCER SCREENING MARKET
4.1. Germany market overview – market trends, market attractiveness analysis, country-wise market revenue (USD)
4.2. Market segmentation based on type of end users (hospitals, laboratory, independent physicians and clinics)
4.2. a. Hospitals Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.2. b. Laboratory Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.2. c. Independent physicians and clinics revenue Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.2. d. Growth drivers and key challenges
4.3. Market segmentation based on type of screening (laboratory, genetic, imaging, biopsy and endoscopy) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
4.3. a. Laboratory Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.3. b. Genetic Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.3. c. Imaging Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.3. d. Biopsy Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.3. e. Endoscopy Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.3. f. Growth drivers and key challenges
4.4. Market segmentation based on type of application (lung, breast, melanoma, kidney and colorectal) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
4.4. a. Lung Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.4. b. Breast Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.4. c. Melanoma Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.4. d. Kidney Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.4. e. Colorectal Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.4. f. Growth drivers and key challenges
CHAPTER 5. OTHERS (THE REST OF EUROPE) CANCER SCREENING MARKET
5.1. Others (the rest of Europe) market overview – market trends, market attractiveness analysis, country-wise market revenue (USD)
5.2. Market segmentation based on type of end users (hospitals, laboratory, independent physicians and clinics)
5.2. a. Hospitals Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.2. b. Laboratory Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.2. c. Independent physicians and clinics revenue Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.2. d. Growth drivers and key challenges
5.3. Market segmentation based on the type of screening type (laboratory, genetic, imaging, biopsy and endoscopy) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
5.3. a. Laboratory Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.3. b. Genetic Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.3. c. Imaging Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.3. d. Biopsy Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.3. e. Endoscopy Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.3. f. Growth drivers and key challenges
5.4. Market segmentation based on type of application (lung, breast, melanoma, kidney and colorectal) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
5.4. a. Lung Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.4. b. Breast Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.4. c. Melanoma Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.4. d. Kidney Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.4. e. Colorectal Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.4. f. Growth drivers and key challenges
CHAPTER 6: COMPETITIVE LANDSCAPE
6.1. F. Hoffman La Roche Ltd
6.1. a. Company snapshot
6.1. b. Product offerings
6.1. c. Growth strategies
6.1. d. Initiatives
6.1. e. Geographical presence
6.1. f. Key numbers
6.2. Bayer AG
6.2. a. Company snapshot
6.2. b. Product offerings
6.2. c. Growth strategies
6.2. d. Initiatives
6.2. e. Geographical presence
6.2. f. Key numbers
6.3. Johnson & Johnson
6.3. a. Company snapshot
6.3. b. Product offerings
6.3. c. Growth strategies
6.3. d. Initiatives
6.3. e. Geographical presence
6.3. f. Key numbers
6.4. Pfizer
6.4. a. Company snapshot
6.4. b. Product offerings
6.4. c. Growth strategies
6.4. d. Initiatives
6.4. e. Geographical presence
6.4. f. Key numbers
6.5. Merck & Co.
6.5. a. Company snapshot
6.5. b. Product offerings
6.5. c. Growth strategies
6.5. d. Initiatives
6.5. e. Geographical presence
6.5. f. Key numbers
CHAPTER 7: CONCLUSION
CHAPTER 8: APPENDIX
8.1. List of tables
8.2. Assumptions
8.3. Research and methodology
8.4. About Netscribes Inc.
Note: The Table of Contents (Toc) provided above contains the targeted coverage. The coverage is subject to change as we progress with the research.
Disclaimer: The report will be delivered within 5-7 business days post payment confirmation
